M3814 (nedisertib) 8445 in a comparison of administration

in a comparison of administration with food v

for use as a precursor to photoswitchable Degraders (PHOTACs)

suppresses ribonucleotide reductase activity with an IC50 of 8

also known as GS-5885

LY117018 exerts antiproliferative effects on breast cancer cell lines

M3814 (nedisertib) 8445 in a comparison of administrationNedisertib (M3814) is a potent and selective inhibitor of DNA dependent Protein Kinase (DNA PK), with an IC50 of <3 nM. Nedisertib (Compound 136) is a potent and selective inhibitor of DNA PK, with an IC50 of <3 nM for DNA PK and <0. 5 for cellular pDNA PK. In combination with IR, Nedisertib shows efficacy in all of the 6 mouse models of human cancer. In all models, a dose of 2 Gy administered daily for 1 week in combination with Nedisertib induces